<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the hereditary ataxias</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the hereditary ataxias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the hereditary ataxias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Puneet Opal, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Huda Y Zoghbi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hereditary ataxias are a genetically heterogeneous group of diseases that may be difficult to distinguish clinically because they are all characterized by motor incoordination resulting from dysfunction of the cerebellum and its connections [<a href="#rid1">1</a>]. With the identification of the gene defects in many of these disorders, the diagnosis now is made more often by genetic testing.</p><p>The hereditary ataxias have traditionally been divided into two main classes:</p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia caused by underlying inborn errors of metabolism; these disorders usually are inherited in an autosomal recessive manner and typically present in childhood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive degenerative ataxias not due to inborn errors of metabolism. These disorders, which are more common, are divided by their mode of inheritance into autosomal dominant, autosomal recessive, X-linked, and mitochondrial forms.</p><p></p><p>The hereditary ataxias caused by inborn errors of metabolism and the episodic, X-linked, and mitochondrial ataxias are discussed in this topic. Autosomal dominant ataxias are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a>.)</p><p>An approach to the initial evaluation of an adult with ataxia is presented separately. (See  <a class="medical medical_review" href="/z/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">AUTOSOMAL DOMINANT ATAXIAS</span><span class="headingEndMark"> — </span>The most common autosomal dominant ataxias are the spinocerebellar ataxias (SCAs)  (<a class="graphic graphic_table graphicRef74269" href="/z/d/graphic/74269.html" rel="external">table 1</a>). Other causes include dentatorubral-pallidoluysian atrophy (DRPLA), which is common in Japan, and the ataxic variant of the Gerstmann-Sträussler-Scheinker syndrome, a prion disease. These disorders are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">AUTOSOMAL RECESSIVE ATAXIAS</span><span class="headingEndMark"> — </span>Approximately 200 gene defects are recognized in the spectrum of autosomal recessive cerebellar ataxias (ARCAs) [<a href="#rid2">2</a>]. Nomenclature is heterogeneous and has evolved to accommodate the primacy of specific genetic diagnoses. Disorders are named based on their order of identification, prominent clinical features, and/or the causative gene  (<a class="graphic graphic_table graphicRef133268" href="/z/d/graphic/133268.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef133271" href="/z/d/graphic/133271.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef133270" href="/z/d/graphic/133270.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef133269" href="/z/d/graphic/133269.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef133265" href="/z/d/graphic/133265.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef133266" href="/z/d/graphic/133266.html" rel="external">table 7</a>).</p><p>The most common ARCAs are Friedreich ataxia and ataxia-telangiectasia [<a href="#rid2">2</a>]. These are discussed separately (see  <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">"Friedreich ataxia"</a> and  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>). In adults, another important genetic cause of ataxia is CANVAS (cerebellar ataxia, neuropathy, and vestibular areflexia syndrome), caused by intronic repeat expansions of the <em>RFC1</em> gene. (See  <a class="medical medical_review" href="/z/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Autosomal recessive ataxias'</a>.)</p><p>Less frequent causes are xeroderma pigmentosum and Cockayne syndrome, which, like ataxia-telangiectasia, are caused by defects in DNA repair mechanisms. (See  <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'DNA repair disorders'</a>.)</p><p>All of these disorders at some point have prominent nonneurologic manifestations, but Friedreich ataxia and ataxia-telangiectasia may be confused in the early stages of the disease. The two disorders can be distinguished by genetic testing [<a href="#rid3">3</a>].</p><p>Many ataxias due to underlying inborn errors of metabolism are inherited in an autosomal recessive manner, and some are treatable with early diagnosis and appropriate therapy. These are discussed below. (See <a class="local">'Ataxias caused by inborn errors of metabolism'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">X-LINKED ATAXIAS</span><span class="headingEndMark"> — </span>X-linked progressive ataxias are a heterogeneous group of rare disorders. Some are pure cerebellar syndromes [<a href="#rid4">4,5</a>], while others encompass additional neurologic abnormalities such as spasticity, deafness, intellectual disability, or dementia [<a href="#rid6">6-9</a>].</p><p>The genetic loci remain unknown in most of these disorders  (<a class="graphic graphic_table graphicRef133272" href="/z/d/graphic/133272.html" rel="external">table 8</a>), with the exception of an early-onset X-linked ataxia that is associated with deafness and loss of vision and links to locus Xq21.2-q24 [<a href="#rid8">8</a>]. Although the X-linked diseases primarily are expressed in males, a small percentage of females have some symptoms because of skewed inactivation of the X chromosome bearing the normal allele. Other patients have ataxia combined with systemic abnormalities such as sideroblastic anemia and adrenal insufficiency.</p><p class="headingAnchor" id="H5"><span class="h2">X-linked sideroblastic anemia with ataxia</span><span class="headingEndMark"> — </span>X-linked sideroblastic anemia with ataxia is a recessive disorder characterized by relatively mild anemia, unresponsiveness to pyridoxine, and nonprogressive cerebellar ataxia [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'X-linked sideroblastic anemias'</a>.)</p><p>The molecular defect resides at Xq13 in the ATP binding cassette subfamily B member 7 (<em>ABCB7</em>) transporter gene. The role of the ABCB7 protein in erythroid cells and the proposed mechanisms by which <em>ABCB7 </em>mutation causes sideroblastic anemia are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'X-linked sideroblastic anemia with ataxia (ABCB7 mutation)'</a> and  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Adrenoleukodystrophy</span><span class="headingEndMark"> — </span>Progressive ataxia and incoordination is an atypical presentation of adrenoleukodystrophy, an X-linked recessive disorder characterized by progressive neurologic dysfunction and primary adrenal insufficiency. This disorder is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MITOCHONDRIAL ATAXIAS</span><span class="headingEndMark"> — </span>Certain mitochondrial disorders can present with a progressive or intermittent ataxia.</p><p class="headingAnchor" id="H8"><span class="h2">Leigh syndrome</span><span class="headingEndMark"> — </span>Leigh syndrome (subacute necrotizing encephalomyelopathy) is an inherited neurodegenerative disorder of infancy or childhood that is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Leigh syndrome'</a>.)</p><p>Summarized briefly, this disorder is characterized by developmental delay or psychomotor regression, signs of brainstem dysfunction, ataxia, dystonia, external ophthalmoplegia, seizures, lactic acidosis, vomiting, and weakness. Peripheral neuropathy with reduced nerve conduction velocity and demyelination also are frequent findings. The prognosis is poor, with survival often being a matter of months after disease onset. Histologic examination reveals bilateral, symmetric necrotizing lesions in the basal ganglia, thalamus, brainstem, and spinal cord. Magnetic resonance imaging shows abnormal white matter signal in the putamen, basal ganglia, and brainstem with T2 images.</p><p>The Leigh syndrome phenotype appears to be related to altered mitochondrial metabolism. Alterations in the mitochondrial respiratory chain complex I, pyruvate dehydrogenase complex (PDHC), or mitochondrial DNA (mtDNA) have been associated with autosomal, X-linked, or mtDNA mutations (maternally inherited Leigh syndrome). A deficiency in cytochrome c oxidase (COX), the fourth multisubunit complex of the respiratory chain, is a common finding that is inherited as an autosomal recessive trait. Mutations in <em>SURF1</em>, a gene located on chromosome 9q34, have been identified in many COX-deficient patients with Leigh syndrome. (See  <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Leigh syndrome'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Ataxia and myoclonus</span><span class="headingEndMark"> — </span>Ataxia and myoclonus can be produced by a variety of mitochondrial lesions. They include large deletions and duplications characteristic of Kearns-Sayre syndrome and maternally inherited point mutations in mitochondrial genes encoding transfer RNA (tRNA), the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), and the MERRF syndrome (myoclonic epilepsy with ragged red fibers) [<a href="#rid12">12-17</a>]. In MELAS, for example, the genetic defect alters amino acid incorporation into the subunits of the oxidative phosphorylation system that are synthesized in the mitochondria, resulting in altered function [<a href="#rid12">12</a>]. In MERRF, on the other hand, an impairment in mitochondrial calcium homeostasis occurs [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H10"><span class="h1">ATAXIAS CAUSED BY INBORN ERRORS OF METABOLISM</span><span class="headingEndMark"> — </span>Numerous hereditary ataxias appear to be caused by inborn errors of metabolism. These ataxias tend to have recessive inheritance, as enzymatic activity of 50 percent in heterozygotes is sufficient for most metabolic pathways to proceed.</p><p>The metabolic pathways involved in these disorders typically have numerous functions. As a result, ataxia is just one component of the clinical phenotype, which, taken as a whole, often points toward the underlying defect. The clinical phenotype can be divided into two general groups: the intermittent ataxias that occur with exacerbations of the underlying biochemical abnormality and the chronic progressive ataxias that are induced by specific enzyme deficiencies  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>).</p><p class="headingAnchor" id="H11"><span class="h2">Intermittent ataxias</span><span class="headingEndMark"> — </span>The most common causes of intermittent ataxias are the aminoacidurias resulting from mutations in urea cycle enzymes, which lead to hyperammonemia and disorders of pyruvate and lactate metabolism  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>). Affected infants with all of these conditions typically display intellectual disability and developmental delay. Nevertheless, establishing the correct diagnosis is important because supportive measures differ.</p><p class="headingAnchor" id="H12"><span class="h3">Urea cycle enzyme deficiencies</span><span class="headingEndMark"> — </span>Neonates with urea cycle enzyme deficiencies typically present with acute neurologic deterioration and hypotonia. Older children may have clumsiness, vomiting, and headaches. In addition, seizures, involuntary movements, and ptosis can occur at the peaks of hyperammonemia, usually induced by stress or ingestion of protein. Inheritance of urea cycle deficits is autosomal recessive, with the important exception of the relatively common ornithine transcarbamylase (OTC) deficiency, which is X-linked. However, some female carriers with OTC convert less ammonia nitrogen to urea and are symptomatic [<a href="#rid18">18-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2929.html" rel="external">"Urea cycle disorders: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Aminoacidurias</span><span class="headingEndMark"> — </span>Ataxia may be seen in children with aminoaciduria, such as intermittent branched-chain ketoaciduria and isovaleric acidemia. This ataxic picture often is combined with seizures, episodic vomiting, and lethargy, similar to that seen in children with urea cycle deficits. The urine usually has a characteristic odor.</p><p>Hartnup disease is a pathogenetically different cause of ataxia, resulting from a defect in renal and intestinal transport of neutral amino acids rather than a metabolic defect. This disorder also is associated with <a class="drug drug_pediatric" data-topicid="12642" href="/z/d/drug information/12642.html" rel="external">niacin</a> deficiency, often leading to symptoms of pellagra (such as rash and confusion). Hartnup disease results from mutations in the solute carrier family 6 member 19 (<em>SLC6A19</em>) gene, which encodes for a sodium-dependent neutral amino acid transporter that is primarily expressed in the kidney and intestine [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Disorders of pyruvate and lactate metabolism</span><span class="headingEndMark"> — </span>Pyruvate dehydrogenase (PDH) deficiency, a less common cause of metabolic intermittent ataxia, is characterized by lactic acidosis, seizures, intellectual disability, ataxia, and spasticity [<a href="#rid23">23</a>]. This condition typically is caused by a mutation in <em>PDHA1</em>, the gene for the E1 alpha subunit of the PDH enzyme complex (Xp22.2-p22.1) [<a href="#rid24">24</a>]. Other less common genetic defects associated with PDH deficiency have been reported, including mutations in the E1 beta [<a href="#rid25">25</a>], E2 [<a href="#rid26">26</a>], and E3 [<a href="#rid27">27</a>] subunits; the E3 binding protein [<a href="#rid28">28</a>]; and the PDH phosphatase enzyme that regulates the PDH complex [<a href="#rid29">29</a>].</p><p>Biotin-responsive multiple carboxylase deficiency is an autosomal recessive ataxia, characterized by ketoacidosis, dermatitis, seizures, myoclonus, and nystagmus [<a href="#rid30">30</a>]. The infantile form can be caused by a variety of mutations in the holocarboxylase synthetase gene at locus 21q22 [<a href="#rid30">30-32</a>]. This enzyme catalyzes the fixation of <a class="drug drug_pediatric" data-topicid="13071" href="/z/d/drug information/13071.html" rel="external">biotin</a> to inactive apocarboxylases, producing four active carboxylases (including pyruvate carboxylase). In children with late-onset (usually juvenile) disease, the defect appears to lie in biotinidase, which catalyzes the removal of biotin from the carboxylases, thereby generating biotin for reutilization [<a href="#rid33">33,34</a>]. The biotinidase gene is located on chromosome 3p25 [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Metabolic ataxias usually are diagnosed by screening biochemical tests when the neurologic abnormalities are first noticed. Based on a positive family history, OTC deficiency and several of the hyperammonemias can be diagnosed from blood samples taken in utero. PDH deficiency can, in addition, be corroborated by a relatively simple biochemical assay on cultured fibroblasts. Despite the identification of individual gene defects, genetic testing, at least at present, is impractical because of the numerous mutations in the relevant genes.</p><p class="headingAnchor" id="H16"><span class="h3">Therapy</span><span class="headingEndMark"> — </span>Although the underlying defect usually cannot be corrected, many of the intermittent ataxias can be indirectly treated:</p><p class="bulletIndent1"><span class="glyph">●</span>Supportive therapy for the urea cycle disorders consists of hydration and dietary protein restriction. No treatment exists for the underlying enzyme deficiency in these disorders except for liver transplantation or, perhaps in the future, hepatocyte transplantation [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4593.html" rel="external">"Hepatocyte transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of the aminoacidurias consists of a high-protein diet. In addition, children with Hartnup disease are given <a class="drug drug_pediatric" data-topicid="12642" href="/z/d/drug information/12642.html" rel="external">niacin</a> (<a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">nicotinamide</a>) supplementation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the disorders of pyruvate and lactate metabolism, PDH deficiency can be treated with a ketogenic diet [<a href="#rid38">38</a>] and dichloroacetate, which increases the activity of PDH by stabilizing the mutant subunit [<a href="#rid39">39,40</a>]. Both infantile [<a href="#rid41">41,42</a>] and late-onset multiple carboxylase deficiency can be treated with pharmacologic doses of <a class="drug drug_pediatric" data-topicid="13071" href="/z/d/drug information/13071.html" rel="external">biotin</a> [<a href="#rid34">34,43,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Biotin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible gene therapies are still experimental [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Progressive ataxias</span><span class="headingEndMark"> — </span>Progressive ataxias induced by enzymatic or transporter deficiency can be seen in a variety of genetic diseases  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>). These disorders typically present in later childhood or adolescence, unlike the intermittent ataxias [<a href="#rid2">2</a>]. The probable explanation for this difference is that cumulative damage must reach a threshold before the clinical signs appear.</p><p>Neurometabolic diseases predominate in this group, which includes Niemann-Pick disease type C, Wilson disease, metachromatic leukodystrophy, neuronal ceroid lipofuscinosis, hexosaminidase deficiencies (eg, juvenile or late-onset Tay-Sachs disease), and adrenoleukodystrophy/adrenomyeloneuropathy  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>). Some of these disorders are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">"Overview of Niemann-Pick disease"</a> and  <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/6195.html" rel="external">"Metachromatic leukodystrophy"</a> and  <a class="medical medical_review" href="/z/d/html/126618.html" rel="external">"Neuronal ceroid lipofuscinosis"</a> and  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Myeloneuropathy'</a>.)</p><p>The diagnosis of a particular neurometabolic disease is usually made from the clinical picture in conjunction with histopathologic findings or biochemical tests. In adrenoleukodystrophy/adrenomyeloneuropathy, for example, the disease is suspected from the X-linked inheritance and confirmed by elevated serum very long-chain fatty acid concentrations.</p><p>In Niemann-Pick disease type C, the diagnosis may be suspected based upon the finding of vertical supranuclear gaze palsy, which is virtually always present in patients with Niemann-Pick disease type C and ataxia. Additional features include splenomegaly and large, lipid-laden foam cells in bone marrow. In Wilson disease, important findings include hepatomegaly and Kayser-Fleischer rings on slit lamp examination  (<a class="graphic graphic_picture graphicRef65925" href="/z/d/graphic/65925.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">"Overview of Niemann-Pick disease"</a> and  <a class="medical medical_review" href="/z/d/html/6257.html" rel="external">"Ocular gaze disorders"</a> and  <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Treatable diseases</span><span class="headingEndMark"> — </span>No cure has been found for the ataxias induced by neurometabolic defects, but specific measures can at least halt progression in a variety of disorders. Some examples are ataxia with <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">vitamin E</a> deficiency, cerebrotendinous xanthomatosis, Refsum disease, and Wilson disease.</p><p class="headingAnchor" id="H2994663374"><span class="h4">Ataxia with vitamin E deficiency</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">Vitamin E</a> deficiency from a variety of causes (eg, malabsorption) can lead to ataxia [<a href="#rid46">46,47</a>]. Several hereditary ataxias also are associated with vitamin E deficiency. The neurologic injury in these disorders may be related to low vitamin E content [<a href="#rid48">48</a>]. Ataxia with vitamin E deficiency is an autosomal recessive disease caused by mutations in the alpha tocopherol transfer protein gene on chromosome 8q13.1 [<a href="#rid49">49-51</a>]. It can present as a slowly progressive ataxia syndrome with neuropathy that can resemble Friedreich ataxia. In addition, some patients develop retinitis pigmentosa [<a href="#rid52">52,53</a>]. High doses of vitamin E typically lead to neurologic improvement, although recovery may be slow and incomplete [<a href="#rid54">54</a>]. Heterozygotes are phenotypically normal but have serum vitamin E concentrations 25 percent lower than normal [<a href="#rid50">50</a>].</p><p>Hypovitaminosis E results from fat malabsorption in patients with abetalipoproteinemia, an autosomal recessive disorder also known as Bassen-Kornzweig disease. The disease is caused by mutations in the microsomal triglyceride transfer protein gene [<a href="#rid55">55</a>]. Defective assembly and secretion of apolipoprotein B (apo B) and apo-B-containing lipoproteins leads to impaired fat absorption, very low serum concentrations of cholesterol and triglyceride, and absent serum beta lipoprotein. The neurologic manifestations include progressive retinal degeneration (caused by coexisting vitamin A deficiency), peripheral neuropathy, and ataxia. Supplementation with <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">vitamin E</a> and the other fat-soluble vitamins early in the clinical course may improve the neuropathy and retinopathy. (See  <a class="medical medical_review" href="/z/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Abetalipoproteinemia'</a>.)</p><p>A similar autosomal recessive ataxic syndrome with <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">vitamin E</a> deficiency occurs in patients with familial hypobetalipoproteinemia in which a mutation in the apo B gene is present [<a href="#rid56">56,57</a>]. Interestingly, some mutations produce no symptoms and are associated with normal serum vitamin E concentrations [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H2355291693"><span class="h4">Cerebrotendinous xanthomatosis</span><span class="headingEndMark"> — </span>Cerebrotendinous xanthomatosis is a relatively rare autosomal recessive cause of progressive ataxia. It is characterized by a block in bile acid synthesis caused by mutations in the mitochondrial sterol 27-hydroxylase gene on chromosome 2q33. The clinical manifestations include ataxia, neuropathy, cataracts, Achilles tendon xanthomas, and accelerated atherosclerosis. The diagnosis is suggested by elevated serum cholestanol in the presence of normal serum cholesterol and can be confirmed by genetic testing. Cholestanol is thought to be responsible for the neurologic toxicity. Treatment with <a class="drug drug_pediatric" data-topicid="91296" href="/z/d/drug information/91296.html" rel="external">chenodeoxycholic acid</a> can markedly reduce both serum and cerebrospinal fluid cholestanol and appears to halt progression of the disease. It should be started early because improvement in established disease is uncommon. (See  <a class="medical medical_review" href="/z/d/html/1692.html" rel="external">"Cerebrotendinous xanthomatosis"</a>.)</p><p class="headingAnchor" id="H2922821882"><span class="h4">Refsum disease</span><span class="headingEndMark"> — </span>Refsum disease is another treatable progressive ataxia. It should be suspected when a patient with autosomal recessive ataxia presents with the additional triad of ichthyosis, retinitis pigmentosa, and neuropathy. Patients with classic Refsum disease are unable to degrade phytanic acid due to deficient activity of phytanoyl-CoA hydroxylase (PhyH) caused by mutations in the <em>PHYH</em> gene. Strict reduction in dietary phytanic acid intake may be associated with a significant improvement in both the peripheral neuropathy and ataxia. (See  <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Refsum disease'</a>.)</p><p class="headingAnchor" id="H562252"><span class="h4">Wilson disease</span><span class="headingEndMark"> — </span>The majority of patients with neurologic Wilson disease have symptoms that fall into one of several categories: dysarthric, dystonic, tremulous, pseudosclerotic (tremor with or without dysarthria), or parkinsonian (see  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Neurologic involvement'</a>). Initially, only one symptom may be present (often unilaterally), but as the disease progresses, complex combinations of neurologic signs and symptoms may develop. Cerebellar ataxia is generally not the sole neurologic manifestation of Wilson disease. The ataxia is typically not clinically relevant, and frank limb ataxia is uncommon.</p><p>Wilson disease is associated with tissue copper accumulation caused by mutations in the gene for ATP7B, a copper transporting ATPase (see  <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>). Symptomatic patients are treated with a chelating agent (<a class="drug drug_pediatric" data-topicid="12685" href="/z/d/drug information/12685.html" rel="external">penicillamine</a> or <a class="drug drug_pediatric" data-topicid="121956" href="/z/d/drug information/121956.html" rel="external">trientine</a>) until stable. Trientine may be preferred in patients with neurologic symptoms, since it appears to be less likely to exacerbate them. (See  <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">"Wilson disease: Management"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">EPISODIC ATAXIAS</span><span class="headingEndMark"> — </span>There are seven varieties of dominantly inherited episodic ataxias (EAs), called EA1 through EA7. Of these, EA1 and EA2 account for the majority of reported cases [<a href="#rid58">58</a>]. The diagnosis of EA is typically made based upon the history and clinical features. Molecular genetic testing is clinically available for some of these disorders [<a href="#rid59">59</a>]. Both EA1 and EA2 respond to treatment with <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a> (250 to 750 mg/day) [<a href="#rid60">60-64</a>], and EA2 responds to <a class="drug drug_general" data-topicid="9095" href="/z/d/drug information/9095.html" rel="external">dalfampridine</a> as discussed below.</p><p class="headingAnchor" id="H284243695"><span class="h2">Episodic ataxia type 1</span><span class="headingEndMark"> — </span>EA1 is characterized by persistent myokymia (rippling of muscles) with brief episodes of cerebellar dysfunction consisting of gait unsteadiness, limb ataxia, dysarthria, titubation, nystagmus, or tremor lasting for only a few minutes [<a href="#rid10">10,65-67</a>]. These spells can be induced by triggers that include physical activity or exercise, stress, environmental temperature, startle, postural change, emotion, hunger, alcohol, intercurrent illness, or caffeine [<a href="#rid68">68</a>]. Most affected individuals have normal or near-normal neurologic function between attacks. However, persistent cerebellar dysfunction and hearing impairment have been reported [<a href="#rid65">65,66</a>]. Disease onset is usually in childhood or adolescence.</p><p>The genetic basis for EA1 is the presence of point mutations in a voltage-gated potassium channel gene, <em>KCNA1</em>, located on chromosome 12p13 [<a href="#rid69">69,70</a>]. Molecular genetic testing for <em>KCNA1</em> mutations is clinically available [<a href="#rid67">67,71</a>]. Typically, the only pathological correlate is minimal atrophy of the anterior cerebellar vermis.</p><p class="headingAnchor" id="H284243702"><span class="h2">Episodic ataxia type 2</span><span class="headingEndMark"> — </span>Patients with EA2 have prolonged attacks of ataxia that can last from a few hours to a few days [<a href="#rid72">72</a>]. Severe vertigo, nausea, and vomiting often are part of the attacks, and gaze-evoked, rebound, or downbeat nystagmus may be evident not only during but also between attacks [<a href="#rid62">62</a>]. These episodes appear to produce cumulative cerebellar injury, as patients often develop persistent cerebellar symptoms and cerebellar atrophy [<a href="#rid73">73</a>]. Thus, subtle cerebellar signs, such as nystagmus and mild clumsiness, and the longer duration of episodes suggest EA2 rather than EA1. The manifestations and rate of progression are variable but usually relatively uniform within a kindred [<a href="#rid62">62</a>]. As with EA1, disease onset is usually late childhood or adolescence.</p><p>EA2 is caused by mutations in the <em>CACNA1A</em> gene that encodes the alpha-1A subunit of a brain-specific P/Q-type calcium channel [<a href="#rid74">74-77</a>] or, in one family, in the gene for the beta-4 subunit of this channel [<a href="#rid78">78</a>]. The alpha-1A subunit mutation also can occur de novo [<a href="#rid63">63</a>]. Mutations in the P/Q calcium channel may cause episodic ataxia in EA2 by reducing calcium-dependent neurotransmitter release in cerebellar Purkinje cells [<a href="#rid79">79</a>]. Molecular genetic testing for <em>CACNA1A</em> mutations is clinically available [<a href="#rid80">80</a>].</p><p>As noted above, <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a> is often effective for reducing the frequency of attacks. In addition, the potassium channel blocker <a class="drug drug_general" data-topicid="9095" href="/z/d/drug information/9095.html" rel="external">dalfampridine</a> (4-aminopyridine) is beneficial, as shown in a randomized controlled trial of 10 patients with EA, including 7 patients with <em>CACNA1A</em> mutations; dalfampridine (5 mg three times a day) was significantly more effective for reducing attack frequency than placebo [<a href="#rid81">81</a>]. In an earlier pilot study, dalfampridine completely prevented attacks of ataxia in two patients and markedly reduced attacks in one [<a href="#rid82">82</a>]. Two of these patients had previously developed an increased frequency of attacks despite treatment with acetazolamide. The proposed mechanism of dalfampridine is increased excitability of cerebellar Purkinje cells with subsequent increased release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) [<a href="#rid82">82</a>]. No trials have compared dalfampridine with acetazolamide in EA2.</p><p class="headingAnchor" id="H284243709"><span class="h2">Episodic ataxia types 3 to 7</span></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic ataxia type 3 – Patients with EA3 (originally designated as EA4) have recurrent, brief (minutes long) attacks of vestibular ataxia, vertigo, tinnitus, and interictal myokymia [<a href="#rid64">64</a>]. The age of onset is variable. The attacks appear to be responsive to <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a>. Genome-wide screening suggests linkage to chromosome 1q42 [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic ataxia type 4 – Patients with EA4 (previously designated as EA3 and also known as periodic vestibulocerebellar ataxia) have recurrent attacks of vertigo, diplopia, tinnitus, and ataxia beginning in early adulthood [<a href="#rid64">64,84</a>]. Ocular manifestations include defective smooth pursuit and gaze-evoked nystagmus [<a href="#rid85">85</a>]. Unlike the other EAs, this form appears to be unresponsive to <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic ataxia type 5 – EA5 has clinical features similar to those of EA2, with attacks lasting hours [<a href="#rid86">86</a>]. EA5 is caused by a mutation in the calcium voltage-gated channel auxiliary subunit beta 4 (<em>CACNB4</em>) gene on chromosome 2q22-23; the same mutation was identified in another family with generalized epilepsy but no ataxia [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic ataxia type 6 – EA6 is caused by a heterozygous mutation in the <em>SLC1A3</em> gene, a member of the solute carrier family that encodes excitatory amino acid transporter 1 (EAAT1), and was identified in an adolescent patient with EA, seizures, migraine, and alternating hemiplegia [<a href="#rid87">87</a>]. Another <em>SLC1A3</em> mutation was found in three family members who had EA but no seizures, migraine, or alternating hemiplegia [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodic ataxia type 7 – EA7 was identified in a single family and has clinical features similar to those of EA2, with the exception that neurologic examination is normal between attacks [<a href="#rid89">89</a>]. Linkage analysis suggested chromosome 19q13 as the gene locus.</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Overlap with other paroxysmal neurologic disorders</span><span class="headingEndMark"> — </span>Mutations in genes encoding ion channels, ion pumps, and glutamate transporters have been associated with EAs, familial hemiplegic migraine (FHM), seizures, and spinocerebellar ataxia (SCA). The following observations have been made:</p><p class="bulletIndent1"><span class="glyph">●</span>Different mutations in the <em>CACNA1A</em> gene encoding the alpha-1A subunit of the P/Q type calcium channel have been identified in EA2, FHM type 1, and SCA type 6.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with EA2 have episodic hemiplegia that may be associated with migraine headaches [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Co-occurrence of FHM with childhood epilepsy and cerebellar ataxia in a single family with a <em>CACNA1A</em> mutation has been reported [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As mentioned above in the discussion of EA6, a heterozygous mutation in the <em>SLC1A3</em> gene was identified in a single adolescent patient with EA, seizures, migraine, and alternating hemiplegia [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EA, FHM, and SCA are often associated with cerebellar atrophy.</p><p></p><p>Disturbances of neuronal excitability may be the underlying mechanism causing these different clinical manifestations. (See  <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">"Hemiplegic migraine", section on 'Familial hemiplegic migraine'</a> and  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">OTHER DISORDERS WITH ATAXIA AND MYOCLONUS</span></p><p class="headingAnchor" id="H22"><span class="h2">Unverricht-Lundborg disease</span><span class="headingEndMark"> — </span>Unverricht-Lundborg disease (ULD) is one form of progressive myoclonus epilepsy that is characterized by myoclonic seizures and progressive ataxia. ULD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Unverricht-Lundborg disease'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Sialidosis</span><span class="headingEndMark"> — </span>Sialidosis (neuraminidase deficiency, mucolipidosis type I) is an autosomal recessive disorder characterized by a defect in the sialidase (neuraminidase) gene on chromosome 6p21.3 [<a href="#rid92">92</a>]. Two main clinical variants of sialidosis have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>Sialidosis type I is characterized by late onset with myoclonus and bilateral macular cherry-red spots.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sialidosis type II is characterized by infantile onset with skeletal dysplasia, intellectual disability, and hepatosplenomegaly.</p><p></p><p class="headingAnchor" id="H2715680495"><span class="h1">HEREDITARY SPASTIC PARAPLEGIAS</span><span class="headingEndMark"> — </span>Other familial genetic syndromes have ataxia as a common associated symptom and, in some instances, phenocopy the familial ataxias. The hereditary spastic paraplegias are the most notable example. (See  <a class="medical medical_review" href="/z/d/html/14152.html" rel="external">"Hereditary spastic paraplegia"</a>.)</p><p class="headingAnchor" id="H3185780224"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83432.html" rel="external">"Patient education: Friedreich ataxia (The Basics)"</a>)</p><p></p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ataxia.org%2F&amp;token=j%2BtF41plvYHq0KcVLVNCgi6FEL66vgnahar6WhxRXNc%3D&amp;TOPIC_ID=6234" target="_blank">National Ataxia Foundation</a>, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.curefa.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEdKUzlV96Q2VAlc69gp03zY%3D&amp;TOPIC_ID=6234" target="_blank">Friedreich's Ataxia Research Alliance</a>, and other nonprofit organizations provide important information for patients and the larger public.</p><p class="headingAnchor" id="H140854770"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – The hereditary ataxias are a genetically heterogeneous group of diseases that are characterized by motor incoordination resulting from dysfunction of the cerebellum and its connections.</p><p></p><p class="bulletIndent1">The hereditary ataxias have traditionally been divided into those caused by underlying inborn errors of metabolism (generally autosomal recessive)  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>) and progressive ataxias not due to inborn errors of metabolism. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant progressive ataxias</strong> – The most common autosomal dominant ataxias are the spinocerebellar ataxias (SCAs)  (<a class="graphic graphic_table graphicRef74269" href="/z/d/graphic/74269.html" rel="external">table 1</a>). Other causes include dentatorubral-pallidoluysian atrophy (DRPLA) and the ataxic variant of the Gerstmann-Sträussler-Scheinker syndrome. (See <a class="local">'Autosomal dominant ataxias'</a> above and  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive ataxias</strong> – The most common autosomal recessive ataxias are Friedreich ataxia and ataxia-telangiectasia  (<a class="graphic graphic_table graphicRef133265" href="/z/d/graphic/133265.html" rel="external">table 6</a>). Less frequent causes are xeroderma pigmentosum and Cockayne syndrome, which, like ataxia-telangiectasia, are caused by defects in DNA repair mechanisms. (See <a class="local">'Autosomal recessive ataxias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked ataxias</strong> – X-linked progressive ataxias are a heterogeneous group of rare disorders. Some are pure cerebellar syndromes, while others encompass additional neurologic abnormalities such as spasticity, deafness, intellectual disability, or dementia. (See <a class="local">'X-linked ataxias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial ataxias</strong> – Certain mitochondrial disorders can present with a progressive or intermittent ataxia. (See <a class="local">'Mitochondrial ataxias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inborn errors of metabolism</strong> – Numerous hereditary ataxias appear to be caused by inborn errors of metabolism. These ataxias tend to have recessive inheritance, as enzymatic activity of 50 percent in heterozygotes is sufficient for most metabolic pathways to proceed (see <a class="local">'Ataxias caused by inborn errors of metabolism'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common causes of intermittent ataxias are the aminoacidurias resulting from mutations in urea cycle enzymes, which lead to hyperammonemia, and disorders of pyruvate and lactate metabolism  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>). (See <a class="local">'Intermittent ataxias'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive ataxias induced by catalytic deficiency can be seen in a variety of diseases. Storage diseases predominate in this group and include Niemann-Pick disease type C, Wilson disease, metachromatic leukodystrophy, the heterogeneous ceroid lipofuscinosis and hexosaminidase deficiencies, and adrenoleukodystrophy/adrenomyeloneuropathy  (<a class="graphic graphic_table graphicRef56126" href="/z/d/graphic/56126.html" rel="external">table 9</a>). (See <a class="local">'Progressive ataxias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episodic ataxias</strong> – There are seven varieties of dominantly inherited episodic ataxias (EAs), called EA1 through EA7. Of these, EA1 and EA2 account for the majority of reported cases. The diagnosis of EA is typically made based upon the history and clinical features. Molecular genetic testing is clinically available for some of these disorders. Both EA1 and EA2 respond to treatment with <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a> (250 to 750 mg/day). (See <a class="local">'Episodic ataxias'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brusse E, Maat-Kievit JA, van Swieten JC. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet 2007; 71:12.</a></li><li><a class="nounderline abstract_t">Synofzik M, Puccio H, Mochel F, Schöls L. Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies. Neuron 2019; 101:560.</a></li><li><a class="nounderline abstract_t">Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007; 6:245.</a></li><li><a class="nounderline abstract_t">Lutz R, Bodensteiner J, Schaefer B, Gay C. X-linked olivopontocerebellar atrophy. Clin Genet 1989; 35:417.</a></li><li><a class="nounderline abstract_t">Spira PJ, McLeod JG, Evans WA. A spinocerebellar degeneration with X-linked inheritance. Brain 1979; 102:27.</a></li><li><a class="nounderline abstract_t">Apak S, Yüksel M, Ozmen M, et al. Heterogeneity of X-linked recessive (spino)cerebellar ataxia with or without spastic diplegia. Am J Med Genet 1989; 34:155.</a></li><li><a class="nounderline abstract_t">Arts WF, Loonen MC, Sengers RC, Slooff JL. X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course. Ann Neurol 1993; 33:535.</a></li><li><a class="nounderline abstract_t">Kremer H, Hamel BC, van den Helm B, et al. Localization of the gene (or genes) for a syndrome with X-linked mental retardation, ataxia, weakness, hearing impairment, loss of vision and a fatal course in early childhood. Hum Genet 1996; 98:513.</a></li><li><a class="nounderline abstract_t">Farlow MR, DeMyer W, Dlouhy SR, Hodes ME. X-linked recessive inheritance of ataxia and adult-onset dementia: clinical features and preliminary linkage analysis. Neurology 1987; 37:602.</a></li><li><a class="nounderline abstract_t">Eunson LH, Rea R, Zuberi SM, et al. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000; 48:647.</a></li><li><a class="nounderline abstract_t">Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.</a></li><li><a class="nounderline abstract_t">Flierl A, Reichmann H, Seibel P. Pathophysiology of the MELAS 3243 transition mutation. J Biol Chem 1997; 272:27189.</a></li><li><a class="nounderline abstract_t">Chomyn A, Enriquez JA, Micol V, et al. The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J Biol Chem 2000; 275:19198.</a></li><li><a class="nounderline abstract_t">Börner GV, Zeviani M, Tiranti V, et al. Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum Mol Genet 2000; 9:467.</a></li><li><a class="nounderline abstract_t">Chomyn A. The myoclonic epilepsy and ragged-red fiber mutation provides new insights into human mitochondrial function and genetics. Am J Hum Genet 1998; 62:745.</a></li><li><a class="nounderline abstract_t">Brini M, Pinton P, King MP, et al. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 1999; 5:951.</a></li><li><a class="nounderline abstract_t">Mancuso M, Filosto M, Mootha VK, et al. A novel mitochondrial tRNAPhe mutation causes MERRF syndrome. Neurology 2004; 62:2119.</a></li><li><a class="nounderline abstract_t">Batshaw ML, Msall M, Beaudet AL, Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986; 108:236.</a></li><li><a class="nounderline abstract_t">Yudkoff M, Daikhin Y, Nissim I, et al. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 1996; 98:2167.</a></li><li><a class="nounderline abstract_t">Gaspari R, Arcangeli A, Mensi S, et al. Late-onset presentation of ornithine transcarbamylase deficiency in a young woman with hyperammonemic coma. Ann Emerg Med 2003; 41:104.</a></li><li><a class="nounderline abstract_t">Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet 2004; 36:999.</a></li><li><a class="nounderline abstract_t">Seow HF, Bröer S, Bröer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet 2004; 36:1003.</a></li><li><a class="nounderline abstract_t">Robinson BH, MacMillan H, Petrova-Benedict R, Sherwood WG. Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complex. J Pediatr 1987; 111:525.</a></li><li><a class="nounderline abstract_t">Dahl HH, Brown GK, Brown RM, et al. Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha gene. Hum Mutat 1992; 1:97.</a></li><li><a class="nounderline abstract_t">Brown RM, Head RA, Boubriak II, et al. Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency. Hum Genet 2004; 115:123.</a></li><li><a class="nounderline abstract_t">Head RA, Brown RM, Zolkipli Z, et al. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol 2005; 58:234.</a></li><li><a class="nounderline abstract_t">Hong YS, Korman SH, Lee J, et al. Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy. J Inherit Metab Dis 2003; 26:816.</a></li><li><a class="nounderline abstract_t">Brown RM, Head RA, Brown GK. Pyruvate dehydrogenase E3 binding protein deficiency. Hum Genet 2002; 110:187.</a></li><li><a class="nounderline abstract_t">Maj MC, MacKay N, Levandovskiy V, et al. Pyruvate dehydrogenase phosphatase deficiency: identification of the first mutation in two brothers and restoration of activity by protein complementation. J Clin Endocrinol Metab 2005; 90:4101.</a></li><li><a class="nounderline abstract_t">Aoki Y, Li X, Sakamoto O, et al. Identification and characterization of mutations in patients with holocarboxylase synthetase deficiency. Hum Genet 1999; 104:143.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Aoki Y, Ishida Y, et al. Isolation and characterization of mutations in the human holocarboxylase synthetase cDNA. Nat Genet 1994; 8:122.</a></li><li><a class="nounderline abstract_t">Dupuis L, Leon-Del-Rio A, Leclerc D, et al. Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency. Hum Mol Genet 1996; 5:1011.</a></li><li><a class="nounderline abstract_t">Wolf B, Grier RE, Allen RJ, et al. Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta 1983; 131:273.</a></li><li><a class="nounderline abstract_t">Wolf B, Heard GS, Weissbecker KA, et al. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985; 18:614.</a></li><li><a class="nounderline abstract_t">Pomponio RJ, Reynolds TR, Cole H, et al. Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. Nat Genet 1995; 11:96.</a></li><li><a class="nounderline abstract_t">Todo S, Starzl TE, Tzakis A, et al. Orthotopic liver transplantation for urea cycle enzyme deficiency. Hepatology 1992; 15:419.</a></li><li><a class="nounderline abstract_t">Busuttil AA, Goss JA, Seu P, et al. The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. Liver Transpl Surg 1998; 4:350.</a></li><li><a class="nounderline abstract_t">Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997; 49:1655.</a></li><li><a class="nounderline abstract_t">McCormick K, Viscardi RM, Robinson B, Heininger J. Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate. Am J Med Genet 1985; 22:291.</a></li><li><a class="nounderline abstract_t">Morten KJ, Beattie P, Brown GK, Matthews PM. Dichloroacetate stabilizes the mutant E1alpha subunit in pyruvate dehydrogenase deficiency. Neurology 1999; 53:612.</a></li><li><a class="nounderline abstract_t">Suormala T, Fowler B, Duran M, et al. Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy in vivo and comparative biochemical studies in vitro. Pediatr Res 1997; 41:666.</a></li><li><a class="nounderline abstract_t">Sakamoto O, Suzuki Y, Li X, et al. Relationship between kinetic properties of mutant enzyme and biochemical and clinical responsiveness to biotin in holocarboxylase synthetase deficiency. Pediatr Res 1999; 46:671.</a></li><li><a class="nounderline abstract_t">Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. Arch Dis Child 1988; 63:1244.</a></li><li><a class="nounderline abstract_t">Lott IT, Lottenberg S, Nyhan WL, Buchsbaum MJ. Cerebral metabolic change after treatment in biotinidase deficiency. J Inherit Metab Dis 1993; 16:399.</a></li><li><a class="nounderline abstract_t">Ginn SL, Cunningham SC, Zheng M, et al. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver. Gene Ther 2009; 16:820.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Guggenheim MA, Iannaccone ST, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580.</a></li><li><a class="nounderline abstract_t">Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurologic disorder from vitamin E deficiency. Neurology 1986; 36:917.</a></li><li><a class="nounderline abstract_t">Traber MG, Sokol RJ, Ringel SP, et al. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med 1987; 317:262.</a></li><li><a class="nounderline abstract_t">Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet 1995; 9:141.</a></li><li><a class="nounderline abstract_t">Gotoda T, Arita M, Arai H, et al. Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein. N Engl J Med 1995; 333:1313.</a></li><li><a class="nounderline abstract_t">Kono N, Ohto U, Hiramatsu T, et al. Impaired α-TTP-PIPs interaction underlies familial vitamin E deficiency. Science 2013; 340:1106.</a></li><li><a class="nounderline abstract_t">Yokota T, Shiojiri T, Gotoda T, et al. Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene. Ann Neurol 1997; 41:826.</a></li><li><a class="nounderline abstract_t">Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci 2004; 25:130.</a></li><li><a class="nounderline abstract_t">Schuelke M, Mayatepek E, Inter M, et al. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr 1999; 134:240.</a></li><li><a class="nounderline abstract_t">Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365:65.</a></li><li><a class="nounderline abstract_t">Young SG, Hubl ST, Smith RS, et al. Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins. J Clin Invest 1990; 85:933.</a></li><li><a class="nounderline abstract_t">Young SG, Bihain B, Flynn LM, et al. Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2. Hum Mol Genet 1994; 3:741.</a></li><li><a class="nounderline abstract_t">Jen JC, Graves TD, Hess EJ, et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007; 130:2484.</a></li><li class="breakAll">Bird TD. Hereditary ataxia overview. GeneReviews. Available at: www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ataxias (Accessed on September 29, 2011).</li><li><a class="nounderline abstract_t">Jen J. Familial Episodic Ataxias and Related Ion Channel Disorders. Curr Treat Options Neurol 2000; 2:429.</a></li><li><a class="nounderline abstract_t">Zasorin NL, Baloh RW, Myers LB. Acetazolamide-responsive episodic ataxia syndrome. Neurology 1983; 33:1212.</a></li><li><a class="nounderline abstract_t">Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 1997; 41:8.</a></li><li><a class="nounderline abstract_t">Yue Q, Jen JC, Thwe MM, et al. De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia. Am J Med Genet 1998; 77:298.</a></li><li><a class="nounderline abstract_t">Steckley JL, Ebers GC, Cader MZ, McLachlan RS. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology 2001; 57:1499.</a></li><li><a class="nounderline abstract_t">Tomlinson SE, Rajakulendran S, Tan SV, et al. Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1. J Neurol Neurosurg Psychiatry 2013; 84:1107.</a></li><li><a class="nounderline abstract_t">Graves TD, Cha YH, Hahn AF, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain 2014; 137:1009.</a></li><li class="breakAll">Hasan SM, D'Adamo MC.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, et al.  (Eds), University of Washington, Seattle, Seattle (WA) 1993. www.ncbi.nlm.nih.gov/books/NBK25442/ (Accessed on December 11, 2018).</li><li><a class="nounderline abstract_t">Gancher ST, Nutt JG. Autosomal dominant episodic ataxia: a heterogeneous syndrome. Mov Disord 1986; 1:239.</a></li><li><a class="nounderline abstract_t">Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet 1994; 8:136.</a></li><li><a class="nounderline abstract_t">Scheffer H, Brunt ER, Mol GJ, et al. Three novel KCNA1 mutations in episodic ataxia type I families. Hum Genet 1998; 102:464.</a></li><li><a class="nounderline abstract_t">Tacik P, Guthrie KJ, Strongosky AJ, et al. Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. Mayo Clin Proc 2015; 90:366.</a></li><li><a class="nounderline abstract_t">Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17.</a></li><li><a class="nounderline abstract_t">Denier C, Ducros A, Vahedi K, et al. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology 1999; 52:1816.</a></li><li><a class="nounderline abstract_t">Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.</a></li><li><a class="nounderline abstract_t">Spacey SD, Hildebrand ME, Materek LA, et al. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol 2004; 56:213.</a></li><li><a class="nounderline abstract_t">Wan J, Carr JR, Baloh RW, Jen JC. Nonconsensus intronic mutations cause episodic ataxia. Ann Neurol 2005; 57:131.</a></li><li><a class="nounderline abstract_t">Riant F, Mourtada R, Saugier-Veber P, Tournier-Lasserve E. Large CACNA1A deletion in a family with episodic ataxia type 2. Arch Neurol 2008; 65:817.</a></li><li><a class="nounderline abstract_t">Escayg A, De Waard M, Lee DD, et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66:1531.</a></li><li><a class="nounderline abstract_t">Kullmann DM. The neuronal channelopathies. Brain 2002; 125:1177.</a></li><li class="breakAll">Spacey S. Episodic ataxia type 2. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ea2 (Accessed on September 29, 2011).</li><li><a class="nounderline abstract_t">Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77:269.</a></li><li><a class="nounderline abstract_t">Strupp M, Kalla R, Dichgans M, et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62:1623.</a></li><li><a class="nounderline abstract_t">Cader MZ, Steckley JL, Dyment DA, et al. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. Neurology 2005; 65:156.</a></li><li><a class="nounderline abstract_t">FARMER TW, MUSTIAN VM. Vestibulocerebellar ataxia. A newly defined hereditary syndrome with periodic manifestations. Arch Neurol 1963; 8:471.</a></li><li><a class="nounderline abstract_t">Damji KF, Allingham RR, Pollock SC, et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996; 53:338.</a></li><li><a class="nounderline abstract_t">Herrmann A, Braathen GJ, Russell MB. [Episodic ataxias]. Tidsskr Nor Laegeforen 2005; 125:2005.</a></li><li><a class="nounderline abstract_t">Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005; 65:529.</a></li><li><a class="nounderline abstract_t">de Vries B, Mamsa H, Stam AH, et al. Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. Arch Neurol 2009; 66:97.</a></li><li><a class="nounderline abstract_t">Kerber KA, Jen JC, Lee H, et al. A new episodic ataxia syndrome with linkage to chromosome 19q13. Arch Neurol 2007; 64:749.</a></li><li><a class="nounderline abstract_t">Jen J, Yue Q, Nelson SF, et al. A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia. Neurology 1999; 53:34.</a></li><li><a class="nounderline abstract_t">Kors EE, Melberg A, Vanmolkot KR, et al. Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology 2004; 63:1136.</a></li><li><a class="nounderline abstract_t">Pshezhetsky AV, Richard C, Michaud L, et al. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet 1997; 15:316.</a></li></ol></div><div id="topicVersionRevision">Topic 6234 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204042" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and management of early- and late-onset cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790538" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303531" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical features and molecular genetics of autosomal recessive cerebellar ataxias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661059" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : X-linked olivopontocerebellar atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/427531" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A spinocerebellar degeneration with X-linked inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816991" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heterogeneity of X-linked recessive (spino)cerebellar ataxia with or without spastic diplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498830" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882866" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Localization of the gene (or genes) for a syndrome with X-linked mental retardation, ataxia, weakness, hearing impairment, loss of vision and a fatal course in early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3470628" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : X-linked recessive inheritance of ataxia and adult-onset dementia: clinical features and preliminary linkage analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11026449" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045952" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9341162" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pathophysiology of the MELAS 3243 transition mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858457" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699170" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529371" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The myoclonic epilepsy and ragged-red fiber mutation provides new insights into human mitochondrial function and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426322" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184630" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A novel mitochondrial tRNAPhe mutation causes MERRF syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944708" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903337" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514690" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Late-onset presentation of ornithine transcarbamylase deficiency in a young woman with hyperammonemic coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286787" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286788" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116190" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1301207" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138885" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049940" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: dihydrolipoamide acetyltransferase (E2) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14765544" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11935326" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pyruvate dehydrogenase E3 binding protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855260" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pyruvate dehydrogenase phosphatase deficiency: identification of the first mutation in two brothers and restoration of activity by protein complementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190325" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Identification and characterization of mutations in patients with holocarboxylase synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842009" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Isolation and characterization of mutations in the human holocarboxylase synthetase cDNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817339" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6883721" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4073853" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Biotinidase deficiency: initial clinical features and rapid diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7550325" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1544622" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Orthotopic liver transplantation for urea cycle enzyme deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9724471" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409363" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050860" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449128" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dichloroacetate stabilizes the mutant E1alpha subunit in pyruvate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128289" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy in vivo and comparative biochemical studies in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590022" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relationship between kinetic properties of mutant enzyme and biochemical and clinical responsiveness to biotin in holocarboxylase synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3196050" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Biotinidase deficiency: a survey of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412000" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebral metabolic change after treatment in biotinidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357713" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069170" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3714053" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The spectrum of neurologic disorder from vitamin E deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037372" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7719340" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566022" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23599266" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impairedα-TTP-PIPs interaction underlies familial vitamin E deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189046" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300460" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931538" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8361539" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312735" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8081360" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575281" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Primary episodic ataxias: diagnosis, pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575281" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Primary episodic ataxias: diagnosis, pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096768" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Familial Episodic Ataxias and Related Ion Channel Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6684259" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Acetazolamide-responsive episodic ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9005860" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600739" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673600" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349320" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24578548" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24578548" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3504247" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Autosomal dominant episodic ataxia: a heterogeneous syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842011" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600245" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Three novel KCNA1 mutations in episodic ataxia type I families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659636" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718690" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical spectrum of episodic ataxia type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371528" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898206" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15293273" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Functional implications of a novel EA2 mutation in the P/Q-type calcium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622542" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nonconsensus intronic mutations cause episodic ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541804" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Large CACNA1A deletion in a family with episodic ataxia type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762541" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023309" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The neuronal channelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023309" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The neuronal channelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734179" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136697" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009908" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13944410" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vestibulocerebellar ataxia. A newly defined hereditary syndrome with periodic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929156" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100538" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : [Episodic ataxias].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116111" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139306" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502476" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A new episodic ataxia syndrome with linkage to chromosome 19q13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408533" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452324" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054950" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
